Chargement en cours...
Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program
The introduction of high-efficacy therapies for relapsing–remitting multiple sclerosis has driven re-evaluation of treatment goals and benefit:risk considerations in treatment choice. In the alemtuzumab Phase II and III clinical trials, patients treated with alemtuzumab 12 mg versus subcutaneous int...
Enregistré dans:
| Publié dans: | Ther Clin Risk Manag |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove Medical Press
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5652900/ https://ncbi.nlm.nih.gov/pubmed/29081658 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S143509 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|